Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients who have the “wet” form of age-related macular degeneration.
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
Sponsored · Whitepaper
Evaluating an asset for development, including the vision, development and continuum capabilities, and global versus local development
PRA Health Sciences
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
